A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma

Wu, Guangzhen; Wang, Qifei; Xu, Yingkun; Li, Quan‐Lin; Cheng, Liang

doi:10.18632/aging.103553

Cited by 78 publications

(79 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, we found three studies that have reported ferroptosis gene signatures. These three studies focused on HCC [54], clear cell renal cell carcinoma [55], and glioma [56]. There are some similarities between our research and these three articles.…”

Section: Discussionmentioning

confidence: 60%

A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma

Peng

Zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Ferroptosis is a new form of regulated cell death (RCD), and its emergence has provided a new approach to the progression and drug resistance of breast cancer (BRCA). However, there is still a great gap in the study of ferroptosis-related genes in BRCA, especially luminal-type BRCA patients.Methods: We downloaded the mRNA expression profiles and corresponding clinical data of BRCA patients from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas (TCGA) databases. Then, we built a prognostic multigene signature with ferroptosis-related differentially expressed genes (DEGs) in the METABRIC cohort and validated it in the TCGA cohort. The predictive value of this signature was investigated in terms of mutations, copy number variations (CNVs), the immune microenvironment and the probability of a response to immunotherapy and chemotherapy.Findings: The patients were divided into a high-risk group and a low-risk group by the ferroptosis-associated gene signature, and the high-risk group had a worse overall survival (OS). The risk score based on the 10 ferroptosis-related gene-based signature was determined to be an independent prognostic predictor in both the METABRIC and TCGA cohorts (HR, 1.41, 95% CI, 1.14-1.76, P = 0.002; HR, 2.19, 95% CI, 1.13-4.26, P= 0.02). Gene set enrichment analysis indicated that the term “cytokine-cytokine receptor interaction” was enriched in the high-risk score subgroup. Moreover, the immune infiltration scores of most immune cells were significantly different between the two groups, and the low-risk group was much more sensitive to immunotherapy and six drugs might have potential therapeutic implications in high- risk group. In addition, we found that amplifications on chromosome 11 accompanied by the deletion of chromosome 1 were enriched in the high-risk subgroup. Finally, a nomogram incorporating a classifier based on the 10 ferroptosis-related genes, tumor stage, age and histologic grade was established. This nomogram showed a favorable discriminating ability and might contribute to clinical decision-making for luminal-type breast carcinoma.

show abstract

Section: Discussionmentioning

confidence: 60%

A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma

Peng

Zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Recently, we found three studies that have reported ferroptosis gene signatures. These three studies focused on HCC [50], clear cell renal cell carcinoma [51], and glioma [52]. There are some similarities between our research and these three articles.…”

Section: Discussionmentioning

confidence: 63%

A Ferroptosis-associated Gene Signature for the Prediction of Prognosis and Therapeutic Response in Luminal-type Breast Carcinoma

Peng

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Ferroptosis is a new form of regulated cell death (RCD), and its emergence has provided a new approach to the progression and drug resistance of breast cancer (BRCA). However, there is still a great gap in the study of ferroptosis-related genes in BRCA, especially luminal-type BRCA patients.Methods: We downloaded the mRNA expression profiles and corresponding clinical data of BRCA patients from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas (TCGA) databases. Then, we built a prognostic multigene signature with ferroptosis-related differentially expressed genes (DEGs) in the METABRIC cohort and validated it in the TCGA cohort. The predictive value of this signature was investigated in terms of mutations, copy number variations (CNVs), the immune microenvironment, tumor purity, related pathway and the probability of a response to immunotherapy and chemotherapy.Findings: The patients were divided into a high-risk group and a low-risk group by the ferroptosis-associated gene signature, and the high-risk group had a worse overall survival (OS). The risk score based on the 10 ferroptosis-related gene-based signature was determined to be an independent prognostic predictor in both the METABRIC and TCGA cohorts (HR, 1.41, 95% CI, 1.14-1.76, P = 0.002; HR, 2.19, 95% CI, 1.13-4.26, P= 0.02). Gene set enrichment analysis indicated that the term “cytokine-cytokine receptor interaction” was enriched in the high risk score subgroup. Moreover, the immune infiltration scores of most immune cells were significantly different between the two groups, and the low-risk group was much more sensitive to immunotherapy and chemotherapy. In addition, we found that amplifications on chromosome 12 accompanied by the deletion of chromosome 21 were enriched in the high-risk subgroup. Pathway score results suggest that the ferroptosis-related gene-based signature show differences in most breast cancer-associated phenotypes. Finally, a nomogram incorporating a classifier based on the 10 ferroptosis-related genes, tumor stage, age and histologic grade was established. This nomogram showed a favorable discriminating ability and might contribute to clinical decision-making for luminal-type breast carcinoma.

show abstract

“…ATP5MC3, also named ATP5G3 [39], encoding a subunit of mitochondrial ATP synthase, was associated with overall survival in clear cell renal carcinoma patients [40]. CARS1, Cysteinyl-TRNA Synthetase 1, associated with tRNA function, has been found associated with the development of inflammatory myofibroblastic tumor [41] and kidney cancer [42].…”

Section: Discussionmentioning

confidence: 99%

Identification and validation of a ferroptosis-related genes based prognostic signature for prostate cancer

Liu

Gao

et al. 2020

Preprint

View full text Add to dashboard Cite

Ferroptosis, an iron-dependent form of selective cell death, involves in the development of many cancers. However, systematic analysis of ferroptosis related genes (FRGs) in prostate cancer (PCa) remains to be clarified. In our research, we collected the mRNA expression profiles and clinical information of PCa patients from TCGA and MSKCC databases. The univariate, LASSO and multivariate Cox regression method were performed to construct prognostic signature in TCGA cohort. Seven FRGs, AKR1C3, ALOXE3, ATP5MC3, CARS1, MT1G, PTGS2, TFRC, were included to establish the risk model, which was validated in MSKCC dataset. Subsequently, we found that high risk group was strongly correlated with copy number alteration load, tumor burden mutation, immune cell infiltration, mRNAsi, immuetherapy and bicalutamide response. Finally, it was identified that overexpression of TFRC could induce proliferation and invasion in PCa cell lines in vitro. These results demonstrated that this risk model based on recurrence free survival (RFS) could accurately predict prognosis in PCa patients, suggesting that FRGs are promising prognostic biomarkers and drug target genes for PCa patients.

show abstract

A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma

Cited by 78 publications

References 30 publications

A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma

A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma

A Ferroptosis-associated Gene Signature for the Prediction of Prognosis and Therapeutic Response in Luminal-type Breast Carcinoma

Identification and validation of a ferroptosis-related genes based prognostic signature for prostate cancer

Contact Info

Product

Resources

About